Eleni A Greenwood1, Lauri A Pasch2, Kanade Shinkai3, Marcelle I Cedars2, Heather G Huddleston2. 1. Department of Obstetrics, Gynecology and Reproductive Sciences, San Francisco, California. Electronic address: eleni.greenwood@ucsf.edu. 2. Department of Obstetrics, Gynecology and Reproductive Sciences, San Francisco, California. 3. Department of Dermatology, University of California San Francisco, San Francisco, California.
Abstract
OBJECTIVE: To [1] characterize depression symptoms over time and [2] test the hypothesis that adverse metabolic parameters would associate with risk of enduring depression risk in women with polycystic ovary syndrome (PCOS). DESIGN: Prospective cohort study. SETTING: University center. PATIENT(S): One hundred sixty-three women with PCOS. INTERVENTION(S): The Beck Depression Inventory Fast Screen (BDI-FS) was self-administered at baseline and follow-up to identify depression risk, using a cutoff score >4. MAIN OUTCOME MEASURE(S): BDI-FS scores. RESULT(S): Median baseline age was 29.0 years, and median follow-up interval was 5.5 years. Fifty-nine of 163 women had positive depression screens at baseline (36%); 52 women (32%) screened positive at follow-up. Median change in BDI-II score was 0 (interquartile range, -2, 1) over the study period. Of the 59 women at risk for depression at baseline, 22 screened negative at follow-up (37%), while 37 women remained at risk (63%). Considering these 59 women with positive depression screens at baseline, higher body mass index (BMI) was associated with increased odds of enduring depression risk at follow-up (adjusted odds ratio = 1.09; 95% confidence interval, 1.00, 1.18), in a multivariate logistic regression model. Compared with women with normal body weight at baseline, obese women (BMI >30 kg/m2) had five-fold increased odds of enduring depression risk at follow-up (adjusted odds ratio = 5.07; 95% confidence interval, 1.07, 24.0). CONCLUSION(S): The prevalence of depression was relatively stable over time in a cohort of women with PCOS. Elevated BMI is a hallmark of enduring depression risk. These results may assist providers in developing targeted intervention strategies to reduce the prevalence of long-term depressive symptoms in women with PCOS.
OBJECTIVE: To [1] characterize depression symptoms over time and [2] test the hypothesis that adverse metabolic parameters would associate with risk of enduring depression risk in women with polycystic ovary syndrome (PCOS). DESIGN: Prospective cohort study. SETTING: University center. PATIENT(S): One hundred sixty-three women with PCOS. INTERVENTION(S): The Beck Depression Inventory Fast Screen (BDI-FS) was self-administered at baseline and follow-up to identify depression risk, using a cutoff score >4. MAIN OUTCOME MEASURE(S): BDI-FS scores. RESULT(S): Median baseline age was 29.0 years, and median follow-up interval was 5.5 years. Fifty-nine of 163 women had positive depression screens at baseline (36%); 52 women (32%) screened positive at follow-up. Median change in BDI-II score was 0 (interquartile range, -2, 1) over the study period. Of the 59 women at risk for depression at baseline, 22 screened negative at follow-up (37%), while 37 women remained at risk (63%). Considering these 59 women with positive depression screens at baseline, higher body mass index (BMI) was associated with increased odds of enduring depression risk at follow-up (adjusted odds ratio = 1.09; 95% confidence interval, 1.00, 1.18), in a multivariate logistic regression model. Compared with women with normal body weight at baseline, obesewomen (BMI >30 kg/m2) had five-fold increased odds of enduring depression risk at follow-up (adjusted odds ratio = 5.07; 95% confidence interval, 1.07, 24.0). CONCLUSION(S): The prevalence of depression was relatively stable over time in a cohort of women with PCOS. Elevated BMI is a hallmark of enduring depression risk. These results may assist providers in developing targeted intervention strategies to reduce the prevalence of long-term depressive symptoms in women with PCOS.
Authors: Salla Karjula; Laure Morin-Papunen; Stephen Franks; Juha Auvinen; Marjo-Riitta Järvelin; Juha S Tapanainen; Jari Jokelainen; Jouko Miettunen; Terhi T Piltonen Journal: J Clin Endocrinol Metab Date: 2020-06-01 Impact factor: 5.958
Authors: Salla Karjula; Riikka K Arffman; Laure Morin-Papunen; Stephen Franks; Marjo-Riitta Järvelin; Juha S Tapanainen; Jouko Miettunen; Terhi T Piltonen Journal: Arch Womens Ment Health Date: 2021-11-29 Impact factor: 3.633